Acute Toxicity Profile and Early Efficacy Results of De-Escalated, Risk-Directed Post-Operative Adjuvant Therapy for Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma: A Phase 2 Trial
Z. Jose(Washington University in St. Louis), Douglas R. Adkins(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Jingxia Liu(Washington University in St. Louis), Patrick Pipkorn(Washington University in St. Louis), Randal C. Paniello(Washington University in St. Louis), Mackenzie Daly(University of Colorado Colorado Springs), Wade L. Thorstad(Washington University in St. Louis), Hiram A. Gay(Washington University in St. Louis), Peter Oppelt(Washington University in St. Louis), Michael E. Jacobs(Washington University in St. Louis), Jessica Ley(Washington University in St. Louis), S. Puram(Washington University in St. Louis), Ryan S. Jackson(Washington University in St. Louis)
International Journal of Radiation Oncology*Biology*Physics
March 11, 2022
Cited by 1
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
|Journal of the National Comprehensive Cancer Network|2022|532